Toutes les études
RecrutementExploratoire thérapeutique (Phase II)Interventionnel

A Phase 2, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Subcutaneously Administered REGN7999 (An Inhibitor of TMPRSS6) in Participants with Iron Overload Due to Non-Transfusion Dependent β-Thalassemia.

This research study is looking at a new medicine called REGN7999. It's for adults (18 years and older) who have a condition called non-transfusion dependent beta-thalassemia (NTDT), which means they don't need regular blood transfusions but still have symptoms. People with NTDT can sometimes build up too much iron in their body, which can be harmful. This study wants to find out if REGN7999 can help reduce these iron levels and if it's safe to use. Half the participants will get the new medicine, and the other half will get a placebo (a dummy medicine) to compare the effects. The main things we'll be checking are how much iron is in the liver and if there are any side effects.

En un coup d'œil

Statut
Recrutement
Phase
Exploratoire thérapeutique (Phase II)
Sponsor
Regeneron Pharmaceuticals Inc.
Objectif d'inscription
10
Démarrer
15 avr. 2025

De quoi parle cette étude ?

This study is designed to learn more about a new medicine called REGN7999. It's for people who have a condition called beta-thalassemia, specifically the type known as non-transfusion dependent beta-thalassemia (NTDT). This means that people with NTDT often don't need regular blood transfusions, but their bodies can still produce red blood cells differently, leading to various health issues.

One common problem for people with NTDT is having too much iron build up in their body, especially in organs like the liver. This can happen over time and can cause serious health problems if not managed. REGN7999 is a new medicine that aims to help the body control these iron levels. We want to see if this medicine can effectively reduce the iron stored in the liver and how safe it is for people to use.

During the study, some participants will receive the new medicine, REGN7999, while others will receive a placebo – which looks exactly like the medicine but contains no active drug. This comparison helps us truly understand the effects of REGN7999. Researchers will be carefully monitoring changes in iron levels in the liver using special scans and also keeping a close eye on participants' overall health and any potential side effects. The goal is to find better ways to manage iron overload in people with NTDT and hopefully improve their quality of life.

Points clés

  • This study is testing a new medicine (REGN7999) for non-transfusion dependent beta-thalassemia (NTDT).
  • It aims to reduce too much iron build-up in the liver.
  • Participants will receive either the new medicine or a placebo (dummy medicine).
  • Iron levels in the liver will be measured using special MRI scans.
  • Safety and side effects will be carefully monitored.
  • The study is for adults aged 18 and over who have NTDT and iron overload.

Qui peut être éligible ?

This study is for adult men and women, meaning you need to be at least 18 years old to take part. There isn't an upper age limit mentioned.

To join, you must have a specific type of blood condition called non-transfusion dependent beta-thalassemia (NTDT). This generally means you have beta-thalassemia but don't need regular blood transfusions every few weeks or months.

Crucially, you must also be experiencing iron overload, which means you have too much iron built up in your body, particularly in your liver. The study will likely check your iron levels to confirm this.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Do you have non-transfusion dependent beta-thalassemia (NTDT)?
  3. Do you have too much iron in your body (iron overload)?
  4. Are you able to attend regular clinic visits and have MRI scans?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to join this study, you would receive either the new medicine (REGN7999) or a placebo, which looks identical but has no active drug. The medicine would be given as an injection under the skin, similar to a flu jab. Since it's a 'double-blind' study, neither you nor your study doctor will know whether you're getting the active medicine or the placebo until the study is over.

You would have regular visits to the study clinic. These visits would involve health checks, blood tests to monitor your iron levels and general health, and special MRI scans to measure the iron concentration in your liver. Researchers will also be checking for any side effects or changes in your health.

The study involves two main parts, and the total duration for each participant, including follow-up, would be decided by the study doctors. You would receive all study-related medicine and tests at no cost.

Risques et avantages potentiels

Taking part in a clinical trial offers the chance to access a new potential treatment before it's widely available, which might help manage your iron overload. You would also be contributing to medical knowledge that could help others with NTDT in the future. However, there are potential risks, just like with any medicine. The new medicine might cause side effects that we don't fully understand yet, or it might not work for you. The regular blood tests and MRI scans might also be inconvenient. Your safety and well-being will be closely monitored throughout the study, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Emplacements (2)

Certains emplacements de site sont approximatifs. Nous améliorons cela — veuillez vérifier avec l'équipe d'essai avant de vous déplacer.
  • —
    Non vérifié
    Grèce
  • —
    Non vérifié
    Italie

Questions fréquentes

What is non-transfusion dependent beta-thalassemia (NTDT)?

It's a type of inherited blood condition where your body doesn't make enough healthy red blood cells, but you don't usually need regular blood transfusions to manage it.

What does 'iron overload' mean?

It means you have too much iron built up in your body, which can happen with certain conditions like NTDT and can damage organs like the liver if not treated.

Qu'est-ce qu'un 'placebo' ?

A placebo is a 'dummy' medicine that looks like the real drug but doesn't contain any active ingredients. It helps researchers compare the effects of the actual medicine fairly.

How will they check my iron levels?

They will use special MRI scans (a type of body scan) to measure how much iron is stored in your liver, as well as regular blood tests.

Puis-je arrêter de participer si je le souhaite ?

Yes, you have the right to withdraw from the study at any time, for any reason, without it affecting your standard medical care.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Phase 2, Two-Part, Randomized, Double-Blind, Placebo-Contr… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.